Pharmacodynamics of L-NMMA in type 1 diabetes patients and control subjects

Journal of Cardiovascular Pharmacology
B A J VeldmanP Smits

Abstract

L-NMMA is widely used in venous occlusion plethysmography studies to determine baseline NO production. Studies using L-NMMA indicate that endothelial dysfunction is present early in the course of diabetic microvascular complications. However, the optimal dose to maximally inhibit NO-production is unknown. To determine the L-NMMA-dose that maximally reduces basal forearm blood flow (FBF). To investigate whether there are any differences in the response to L-NMMA between non-complicated type 1 diabetes patients and control subjects. In eight non-complicated type 1 diabetes patients and nine healthy subjects FBF-responses to intra-arterial infusion of increasing doses of L-NMMA (0.01-1.6 mg/min/dL forearm volume [FAV]) were measured using the perfused forearm technique. Infusion of 0.8 mg/min/dL maximally reduced FBF. The dose of 1.6 mg/min/dL did not additionally reduce FBF. No differences existed between non-complicated type 1 diabetes patients and controls with regard to EC50 (0.017 +/- 0.02 resp. 0.22 +/- 0.02 mg L-NMMA/min/dL) or maximal vasoconstrictive response (Delta FBF: 1.13 +/- 0.4 resp. 0.97 +/- 0.4 mL/min/dL). Throughout the study blood pressure increased significantly in both groups, possibly reflecting a systemic va...Continue Reading

References

Oct 1, 1994·British Journal of Clinical Pharmacology·J R CockcroftJ M Ritter
Mar 1, 1996·Journal of the American College of Cardiology·S B WilliamsM A Creager
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·R A CohenC J Garland
Mar 21, 1998·Journal of the American College of Cardiology·F K TimimiM A Creager
Jan 5, 2000·Journal of the American Society of Nephrology : JASN·Roland VeelkenR Bernd Sterzel
Apr 19, 2000·The Journal of Clinical Endocrinology and Metabolism·N G MajmudarG A Ford

❮ Previous
Next ❯

Citations

Dec 12, 2012·Anesthesiology·Kirsten F SmitBenedikt Preckel
Jul 25, 2013·Anesthesiology·Kirsten F SmitBenedikt Preckel
Jul 16, 2009·American Journal of Physiology. Endocrinology and Metabolism·Marlies BosselaarCees J Tack

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.